```html

Zollinger‑Ellison Syndrome (Gastrinoma): A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas or duodenum and secrete excessive amounts of the hormone gastrin. Elevated gastrin stimulates the stomach lining to produce large volumes of gastric acid, leading to severe peptic ulcer disease and a host of gastrointestinal symptoms.

Who it affects: ZES can develop at any age but most commonly presents in adults between the ages of 30‑60. Both men and women are affected, with a slight male predominance in some series (≈55% male). About 20‑25% of cases occur as part of the inherited condition multiple endocrine neoplasia type 1 (MEN‑1), which carries additional endocrine tumors (parathyroid, pituitary).

Prevalence: The syndrome is estimated to affect roughly 1–3 people per million worldwide. Because gastrinomas are often small and present with nonspecific symptoms, the true incidence may be slightly higher.

Key sources: Mayo Clinic; NIH.

Symptoms

Symptoms arise from chronic hyperacidity and from the mass effect of the tumor itself. The following list is comprehensive; not every patient experiences all of these.

Gastrointestinal symptoms

• Refractory peptic ulcers – often multiple, larger than usual, and located beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – burning or crampy, may be worse after meals.
• Diarrhea – up to 3–5 watery stools daily; caused by acid‑induced irritation and malabsorption.
• Steatorrhea (fatty stools) – excess acid inactivates pancreatic enzymes, leading to fat maldigestion.
• Nausea / vomiting – especially when ulcers bleed.
• Gastroesophageal reflux disease (GERD) – acid overload can worsen heartburn.

Systemic symptoms

• Weight loss – due to malabsorption and decreased appetite.
• Fatigue – chronic anemia from occult GI bleeding.
• Electrolyte disturbances – hypokalemia and metabolic alkalosis from persistent vomiting.

Signs related to the tumor itself

• Palpable abdominal mass – rare, usually when the gastrinoma is large.
• MEN‑1 manifestations – hyperparathyroidism (kidney stones, bone pain), pituitary adenoma (headaches, visual changes).

Causes and Risk Factors

Primary cause

Gastrinomas arise from neuroendocrine cells that acquire genetic mutations leading to uncontrolled growth and gastrin secretion. Most are sporadic, but about one‑quarter are linked to the hereditary syndrome multiple endocrine neoplasia type 1 (MEN‑1).

Genetic and molecular factors

• MEN‑1 gene mutation – loss‑of‑function mutations on chromosome 11q13.
• Somatic mutations in MEN1, p53, and KRAS have been identified in sporadic gastrinomas.

Risk factors

• Family history of MEN‑1 or known MEN‑1 mutation.
• Previous radiation to the abdomen (rarely implicated).
• Chronic atrophic gastritis or H. pylori infection does not cause ZES but can coexist and worsen ulcer disease.

Overall, no lifestyle habits (smoking, alcohol) are proven to cause ZES, though they can aggravate ulcer symptoms.

Diagnosis

Diagnosis combines clinical suspicion (refractory ulcers, high gastrin levels) with biochemical and imaging studies.

Biochemical testing

• Fasting serum gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when gastric pH < 2. A level 10‑fold above normal with low pH confirms hypergastrinemia.
• Secretin stimulation test: In ZES, paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) differentiates from other causes.
• Stool tests: Fecal fat quantification if steatorrhea suspected.

Imaging studies

• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Detects small neuroendocrine tumors with high sensitivity (≈ 85‑95%).
• Endoscopic ultrasound (EUS): Highly accurate for lesions < 2 cm in the pancreas/duodenum.
• CT or MRI abdomen: Provides anatomic detail, evaluates for metastasis (especially liver).
• Selective arterial secretin stimulation: Rare, used when non‑invasive imaging is inconclusive.

Endoscopic evaluation

Upper endoscopy (EGD) is performed to document ulcer location, size, and to obtain biopsies to rule out malignancy or H. pylori infection.

Diagnostic criteria (summary)

1. Fasting gastrin > 1000 pg/mL or > 10× upper limit with gastric pH < 2.
2. Positive secretin stimulation test.
3. Imaging confirming a gastrin‑secreting tumor (or evidence of metastatic disease).

Treatment Options

Management aims to control acid hypersecretion, remove or reduce tumor burden, and monitor for recurrence.

Acid‑blocking medications (first line)

• Proton pump inhibitors (PPIs) – e.g., omeprazole, esomeprazole, pantoprazole. High‑dose regimens (often 2–4× standard dose) are required; some patients need continuous IV infusion initially.
• Histamine‑2 receptor antagonists (H2 blockers) – less effective alone but can be added for breakthrough symptoms.

These agents heal ulcers, stop bleeding, and improve quality of life. Long‑term PPI use should be monitored for nutrient malabsorption (B12, magnesium) and bone health.

Surgical management

• Curative resection – Enucleation or segmental pancreatectomy for localized gastrinomas (< 2 cm) with negative margins.
• Debulking surgery – For metastatic disease, removing > 90% of tumor burden can reduce gastrin levels and improve symptom control.
• Liver metastasis treatment – Options include resection, radiofrequency ablation, or hepatic arterial embolization.

Curative surgery is possible in ~30‑40% of sporadic cases; MEN‑1 patients often have multifocal disease, making complete resection less likely.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogs (octreotide or lanreotide) – Inhibit gastrin release and may shrink neuroendocrine tumors.
• Targeted therapy – Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; shown to improve progression‑free survival.
• Chemotherapy – Generally reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑based combos.

Lifestyle and supportive measures

• Small, low‑fat meals to reduce acid stimulus.
• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs unless prescribed with protective agents.
• Supplement vitamin B12, calcium, magnesium if long‑term PPI therapy is required.
• Regular bone density testing for osteoporosis risk.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; never skip doses.
• Schedule follow‑up labs – Check fasting gastrin, vitamin B12, magnesium, and liver function every 6‑12 months.
• Nutrition – Emphasize a balanced diet rich in protein, moderate in complex carbohydrates, low in simple sugars and saturated fats.
• Hydration – Diarrhea can lead to dehydration; aim for 2–3 L of fluid daily, using oral rehydration solutions if needed.
• Stress reduction – Stress can exacerbate ulcer pain; consider mindfulness, yoga, or counseling.
• Monitor for recurrence – Keep a symptom diary; report new abdominal pain, change in stool pattern, or unexplained weight loss promptly.

Support resources

Joining patient advocacy groups such as the North American Neuroendocrine Tumor Society (NeT) can provide education, peer support, and updates on clinical trials.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be mitigated in the following ways:

• Genetic counseling for families with known MEN‑1 mutations; early screening (annual fasting gastrin, imaging) is recommended.
• Avoid chronic use of ulcer‑causing medications (e.g., high‑dose NSAIDs) unless protected by PPIs.
• Prompt treatment of H. pylori infection – While not a cause of ZES, eradication reduces the overall ulcer burden.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Severe peptic ulcer disease – perforation, massive gastrointestinal bleeding, and need for emergent surgery.
• Gastrointestinal strictures – from chronic ulcer scarring, causing obstruction.
• Malabsorption and nutrient deficiencies – especially fat‑soluble vitamins (A, D, E, K) due to steatorrhea.
• Metastatic disease – Approximately 50‑60% of gastrinomas are malignant at diagnosis; liver is the most common site.
• Osteoporosis – Chronic acid hypersecretion and long‑term PPI use can impair calcium absorption.
• MEN‑1 associated complications – Hyperparathyroidism (kidney stones, bone disease) and pituitary tumors (visual loss, hormonal disturbances).

When to Seek Emergency Care

References

• Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/
• National Institutes of Health (NIH). Gastrinoma. https://www.ncbi.nlm.nih.gov/books/NBK459
• American College of Gastroenterology. Guidelines for the Management of Gastric Acid–Related Disorders. 2022.
• World Health Organization. Neuroendocrine Tumors: Classification and Management. 2021.
• Richards, D. et al. “Outcomes of Surgical Resection for Zollinger‑Ellison Syndrome.” J Gastrointest Surg, 2020.
• Capurso, G. et al. “Somatostatin Analogs in Gastrinoma Management.” Pancreas, 2019.

```